Q-omics provides the consensus-scored OPTC profile across patient tissues and cancer cell-line models. OPTC expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, OPTC is differentially expressed in 9, with the highest sampling consensus in BLCA. Additionally, OPTC RNA expression shows 10,516 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, BLCA, and THYM as cancer lineages where OPTC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OPTC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OPTC survival associations across molecular data types. OPTC RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OPTC RNA expression–survival associations across cancer types. High OPTC expression shows unfavorable associations in KIRC and ACC, but favorable associations in LGG, UCEC, STAD and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for OPTC RNA expression.
This table summarizes OPTC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for OPTC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OPTC shows lower tumor expression in BLCA, STAD, BRCA and PRAD and higher tumor expression in LIHC and KICH. The BLCA box plot shows higher OPTC RNA expression in normal versus tumor tissue (log2 FC = −0.462, t-test p < 0.001).
This table shows molecular features associated with OPTC in patient tissues and cancer cell lines. In patient samples, OPTC shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, OPTC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LUNG_SCLC.
